Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OmnicellMEX:OMCL 76 Forward PE Ratio is 22.48 as of Jul. 19, 2026. GuruFocus rates MEX:OMCL with a GF Score™ of 76/100 and a GF Value™ of MXN643.79. The stock has 7 warning signs investors should review. Among 313 Healthcare Providers & Services companies, Omnicell ranks worse than 60.38% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Omnicell Forward PE Ratio Related Terms
Omnicell Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Omnicell's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omnicell Forward PE Ratio Chart
Omnicell Annual Data
Trend
2021-12
2024-12
2025-12
Forward PE Ratio
43.48
26.07
29.13
Omnicell Quarterly Data
2021-03
2021-09
2021-12
2022-03
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
38.17
35.71
43.48
48.78
26.07
26.45
39.98
30.91
29.13
30.69
MEX:OMCL vs TDOC, SDGR, OMDA: Forward PE Ratio Comparison
For the Health Information Services subindustry, Omnicell's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omnicell Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Omnicell's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Omnicell's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Omnicell (MEX:OMCL) has a Forward PE Ratio of 22.48 as of Jul. 19, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Omnicell and its competitors. According to the industry distribution chart, Omnicell ranks #189 out of 313 companies in the Healthcare Providers & Services industry, placing it in the top 60.4%.
Is Omnicell's Forward PE Ratio too high?
Omnicell's current Forward PE Ratio is 22.48. The Healthcare Providers & Services industry median Forward PE Ratio is 18.61. Omnicell's value of 22.48 is 20.8% above this industry median. Based on the distribution chart, Omnicell ranks #189 out of 313 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Omnicell has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Omnicell's Forward PE Ratio compare to TDOC and SDGR?
According to the Healthcare Providers & Services industry distribution chart, Omnicell ranks #189 out of 313 companies for Forward PE Ratio. This places Omnicell in the lower half of its industry. The industry median Forward PE Ratio is 18.61. Omnicell's value of 22.48 is 20.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 18.61, based on 313 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Omnicell's current Forward PE Ratio of 22.48 is 20.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Omnicell and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 18.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omnicell's current Forward PE Ratio is 22.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omnicell stock overvalued right now?
Omnicell (MEX:OMCL) has a current Forward PE Ratio of 22.48. The stock's GF Value™ is MXN643.79, compared to a current price of MXN761.16 — trading 18.2% above its estimated fair value. The current Forward PE Ratio is 22.48 and 20.8% above the Healthcare Providers & Services industry median of 18.61. Omnicell's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Omnicell (MEX:OMCL), the current Forward PE Ratio is 22.48 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omnicell (MEX:OMCL) Overvalued in 2026?
Based on GuruFocus' analysis, Omnicell stock appears to be overvalued.
The current stock price of MXN761.16 is trading 18.2% above its estimated GF Value™ of MXN643.79.
Key valuation signals for MEX:OMCL:
Forward PE Ratio: 22.48
GF Value™: MXN643.79 vs. price of MXN761.16 (18.2% above fair value)
Industry Position: 20.8% above the Healthcare Providers & Services median (#189 of 313)
No single metric tells the full story. See the MEX:OMCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
76GF Score
Get the complete analysis for MEX:OMCL
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:OMCL has been successfully added to your 
